Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cinrebafusp alfa |
| Synonyms | |
| Therapy Description |
Cinrebafusp alfa is a bispecific antibody that targets both TNFRSF9 (CD137; 4-1BB) and ERBB2 (HER2), potentially resulting in enhanced anti-tumor immune response against Erbb2 (Her2)-positive tumor cells (PMID: 31138587, PMID: 39235868). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cinrebafusp alfa | PRS-343|PRS 343|PRS343 | HER2 (ERBB2) Antibody 79 TNFRSF9 Antibody 36 | Cinrebafusp alfa is a bispecific antibody that targets both TNFRSF9 (CD137; 4-1BB) and ERBB2 (HER2), potentially resulting in enhanced anti-tumor immune response against Erbb2 (Her2)-positive tumor cells (PMID: 31138587, PMID: 39235868). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03330561 | Phase I | Cinrebafusp alfa | PRS-343 in HER2-Positive Solid Tumors | Completed | USA | 0 |